(CercleFinance.com) – Inventiva announces the lifting of the previously announced voluntary pause in screening and randomization for its NATiV3 clinical study, evaluating its lanifibranor in NASH (non-alcoholic fatty liver disease) and the resumption of screening activities on its sites.
The biopharmaceutical company recalls having decided on this suspension following a suspicion of an unexpected serious adverse reaction (SUSAR) in a patient in the study, in order to implement the recommendations of the independent Data Monitoring Committee.
Patient screening is resuming at sites operating under the aegis of the central IRB in the United States, and the others are expected to gradually resume over the coming weeks. The first visit of the last patient is planned for the first half of 2024.
Copyright © 2024 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends using the buttons below.
